aTyr Pharma files amended at-the-market offering for up to $79.99 million

aTyr Pharma filed a prospectus supplement dated November 6, 2026 that amends and restates terms for an at-the-market stock offering through Jefferies LLC. Under the arrangement, the company may offer and sell common stock with an aggregate offering price of up to $215.0 million through Jefferies, inclusive of $65.0 million sold prior to a December 2024 amendment to the sales agreement.¹ As of the filing date, shares with an aggregate offering price of up to $79,994,251 remained unsold under the sales agreement.¹ The last reported sale price of aTyr's common stock on Nasdaq was $6.03 per share on November 5, 2026.¹

The filing also recaps clinical data for aTyr's lead candidate, efzofitimod, in pulmonary sarcoidosis. In the Phase 3 EFZO-FIT study, the trial did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48, with the dose reducing to an average of 2.79 mg for the 5.0 mg/kg efzofitimod group versus 3.52 mg for placebo (p=0.3313).¹ However, the study demonstrated a clinically meaningful improvement in the King's Sarcoidosis Questionnaire-Lung score at week 48 for the 5.0 mg/kg efzofitimod dose compared to placebo (p=0.0479)¹, the company said.

Following FDA discussions, aTyr announced in September 2026 that it had reached alignment with the FDA on a Proposed Phase 3 Study protocol and expected to initiate study-related activities in the fourth quarter of 2026.¹ The company also disclosed a corporate restructuring: in August 2026, its board approved a plan that reduced total workforce by approximately 60% to 20 full-time employees.¹ Separately, a 1-for-40 reverse stock split became effective October 28, 2026, with shares trading split-adjusted on Nasdaq beginning October 29, 2026.¹